INCYTE CORP (INCY) SEC Filings, Sep-Oct 2025

Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte Corp (INCY), reported a disposition of company shares on 10/01/2025. The filing shows 1,569 shares of common stock were disposed of at a price of $86.70 per share under transaction code F, and the reporting person remains the beneficial owner of 65,819 shares following the transaction. The filing explains the 1,569 shares represent shares withheld automatically by the issuer to satisfy tax-withholding obligations associated with the settlement of previously reported restricted stock units.

The report also notes that of the remaining position, 59,858 shares are issuable pursuant to previously reported restricted stock units that have not vested. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025.

Heeson Lee, EVP and Head of Incyte International, filed a Form 4 reporting changes in beneficial ownership of INCY common stock. On 10/01/2025 the filing shows 463 shares were disposed of (reported under Code F) at a price of $86.7 per share to satisfy tax withholding obligations tied to previously granted restricted stock units. After the reported transaction the filing shows beneficial ownership of 32,315 shares; the filer discloses that this total includes 26,167 shares issuable under previously reported unvested RSUs. The form is signed by an attorney-in-fact on 10/03/2025.

Incyte Corporation reported a leadership change in its finance organization. The Board of Directors appointed Thomas Tray, currently Vice President, Finance and Chief Accounting Officer, to also serve as the company’s principal financial officer, effective as of September 16, 2025.

Tray, age 48, has been with Incyte since 2005, starting as Manager of External Reporting and later serving as Vice President and Controller before his current roles. He holds a B.S. in Accounting from Mount Saint Mary’s University and an Executive MBA in Pharmaceutical Marketing from Saint Joseph’s University. The company states there are no special arrangements related to his appointment, no family relationships with directors or executive officers, and no material related-party transactions requiring disclosure.

Incyte Corp director Paul J. Clancy acquired 285 shares of Incyte common stock on 09/30/2025 at a price of $84.81 per share through restricted shares issued in lieu of quarterly director retainer fees under the company’s Amended and Restated 2010 Stock Incentive Plan; those restricted shares are reported as fully vested.

Following this transaction, the reporting person beneficially owns 23,235 shares in total, which includes an aggregate of 2,518 shares issuable upon previously reported restricted stock units that have not vested.

Edmund Harrigan, a director of Incyte Corp (INCY), acquired 289 shares of common stock on 09/30/2025 at a price of $84.81 per share. The shares were issued as restricted shares under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of a quarterly director retainer, and the filing states the restricted shares are fully vested. After this transaction, the reporting person beneficially owns 20,608 shares, which includes 2,518 shares issuable under previously reported restricted stock units that have not vested. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Form 144 notice for INCY (Incyte Corp): An individual, Sheila Denton, filed a proposed sale of 599 common shares to be executed through Morgan Stanley Smith Barney LLC on 10/02/2025 on the NASDAQ. The filing shows those 599 shares were acquired on 10/02/2025 by exercising stock options and paid in cash. The form lists six prior open-market sales by the same person during Jul–Sep 2025 totaling 6,165 shares sold across multiple dates with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information.

Incyte Corp (INCY) reported equity awards to David H. Gardner, EVP and Chief Strategy Officer, on 09/22/2025. The filing shows a grant of 9,429 restricted stock units (RSUs) that vest 25% annually over four years and are settled one-for-one in common stock. The report also lists 23,573 performance shares that can pay up to 200% of one share based on relative total shareholder return versus a fixed peer group over a three-year performance period beginning 01/01/2025, with earned shares vesting on the third anniversary. Additionally, 42,899 employee stock options were granted at an $84.73 exercise price, exercisable in 37 installments with the first 25% after one year and monthly vesting thereafter, expiring 09/22/2035. The filing shows the reporting person beneficially owned 9,429 common shares and had derivative interests underlying 23,573 performance shares and 42,899 options following the grants.

Incyte Corp (INCY) Form 3 filed for David H. Gardner. The filing, reporting an event dated 09/22/2025, shows Mr. Gardner identified as an EVP, Chief Strategy Officer and officer/director of the issuer. The report states no securities are beneficially owned by the reporting person as of the event date. The form is signed by an attorney-in-fact on 09/24/2025.

Form 144 filing for INCY by named seller Barry Flannelly. The filer notifies a proposed sale of 17,447 common shares valued at $1,487,531.22 to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 09/18/2025. The shares were acquired on 09/18/2025 by stock option exercise from the issuer and payment was made in cash the same day. The filing also lists five prior Common share sales by Barry Flannelly during July–August 2025 totaling 101,435 shares for gross proceeds of $8,631,432.53. The notice includes the required attestation about possession of material non-public information.